APYX Medical’s Renuvion Becomes the Only Device that is FDA-cleared for Use Following Liposuction in Aesthetic Body Contouring Procedures
CLEARWATER, Fla., May 2, 2023 / PRNewswire / — Apyx Medical Corporation (NASDAQ: APYX), the manufacturer of the proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the use of its APR Handpiece in procedures for coagulation of soft tissues following liposuction, the most popular plastic surgery procedure in the world.
“We are thrilled to announce this newest clearance, making Renuvion the only device cleared to be used after liposuction procedures,” said Todd Hornsby, Executive Vice President. “This is the 4th 510(k) clearance we have received from the FDA in the past 11 months and highlights our commitment to providing evidence-based outcomes and clearances to further demonstrate the safety and efficacy of our Renuvion technology.”
Already cleared by the FDA for the treatment of neck laxity, facial renewal procedures, and the contraction of soft tissue, Renuvion’s latest 510(k) clearance allows physicians to set a new standard for liposuction results when it comes to minimally invasive body contouring.
Liposuction effectively removes fat volume, leaving behind empty space which may increase the appearance of excess or loose skin. Renuvion goes beneath the surface and applies precise energy directly to the source of the loose skin. This energy contracts the collagen fibers and pulls the skin down, closer to the muscle, for a more contoured appearance. By adding Renuvion to these procedures, physicians have another tool to help them obtain optimal liposuction results.